February, 2019

Boston, USA

Register Interest 

Day One
Monday February 26th, 2018

Day Two
Tuesday February 27th, 2018

08.00
Registration & Coffee

09.00
Chairperson’s Opening Remarks

Colliding Cell Therapy with Precision CRISPR

09.10
Using CRISPR/Cas9 to Illuminate Stem Cell Organization and Dynamics

Synopsis

  • A systematic approach for generating knock-ins in stem cells
  • Identifying and improving precision of HDR events
  • Use of live imaging and gene editing to explore cell states

09.40
Gene Delivery & Gene Editing in the Retina

Synopsis

  • Overview of methods for “in vivo” delivery to retina
  • Genes delivery to different cell types in retina
  • Crispr/Cas9 mediated gene editing in the retina

10.10
Using CRISPR to Modulate Immunosuppressive Pathways in CAR T Cell Products

Synopsis

  • Identified a highly specific gRNA for knockout of the TGFβRII gene in primary CAR T cells using CRISPR
  • Validated that TGFβRII KO mediated CAR T cell products resistant to TGFβ-mediated suppression
  • Identified a TGFβ RNA signature that is induced when CAR T cells see antigen expressing tumor cells in the presence of TGFβ; this signature is reversed when TGFβRII is knocked out by CRISPR

10.40
Morning Refreshments

11.10 Nucleic Acid Detection with RNA-Guided RNA Targeting CRISPR Cas13

  • Discovery of novel CRISPR enzymes, including CRISPR-Cas13
  • Biochemical characterization of CRISPR-Cas13 for RNA targeting
  • Development of CRISPR-Cas13 for highly sensitive and specific nucleic acid diagnostics

Jonathan S. Gootenberg, Ph.D. Candidate, Broad Institute of MIT and Harvard

11.40 Latest Advancement in Gene Editing and Functional Genomics Screening Tools

  • Invitrogen CRISPR-Cas9 RNP system and LentiArray CRISPR libraries
  • Latest tools and protocols for precision editing
  • Complete workflow solutions for cell model generation and functional genomics screening

Namritha Ravinder, R&D Scientist, Cell Engineering, Thermo Fisher

12.10 In Vivo CRISPR Models in the Drug Discovery Process

  • Impact of genome editing in DD
  • How CRISPR models compare with previous models
  • Future perspectives and applications

Danilo Madalo, Laboratory Head, Novartis

12.40 Enhanced Proofreading Governs CRISPR-Cas9 Targeting Accuracy

  • DNA target binding reorients Cas9 protein domains to trigger nuclease activity
  • A region of the protein called REC3 functions as a master controller for protein activation
  • Minor alterations within the REC3 domain alters the differential between on- and off-target activity and results in a hyper-accurate Cas9 protein (HypaCas9)

Janice Chen, Scientist – Jennifer Doudna’s lab, Berkeley

11.10 Large Scale Production of Engineered T Cells Using CRISPR/Cas9

  • Gee editing enhances potential of CAR-T cells therapy
  • Sourcing of cGMP grade guide RNA, Cas9 and RNPs
  • Understanding of gene editing in manufacturing setting

Shantanu Kumar, Senior Scientist, Juno Therapeutics

11.40 High Fidelity Genome Editing Using RNP Complexes with a Novel Mutant HiFi Cas9

  • Off-target effects (OTEs) remain a problem for genome editing, even using RNP methods
  • Several mutant Cas9 enzymes have been described that lower OTEs but have low on-target activity when used in RNP methods
  • A new HiFi Cas9 was developed with high on-target and low off-target activity as RNP

Mark A. Behlke, Chief Scientific Officer, Integrated DNA Technologies

12.10 CRISPR Editing in Hematopoietic Stem and Progenitor Cells for the Treatment of Hematologic Diseases

  • Determining the optimal editing strategy
  • Utilizing the Editas platform in a disease setting
  • Editing of Adult Human HSCs to Increase HbF Protein
  • Repopulating the Blood System with Edited HSCs

 

Jack Heath, Senior Research Associate, Editas Medicine

12.40 CAMT: Genome Editing Rescue of a Novel MPL Mutant in Primary Cord Blood HSPCs

  • Function of mutant Mpl receptor can be rescued using 2 approaches: autophagy-dependent cell surface delivery and CRISPR-Cas9 gene Editing
  • Edited primary cord blood CD34+ retained their ability to differentiate into platelet-producing megakaryocytes in vitro
  • HDR and NHEJ editing events, alone or in combination, were able to restore the receptor’ function
  • Proof-of-principle for a direct therapeutic application of genome editing in CAMT

Cedric Cleyrat, Assistant Research Professor & Genome Editing Consultant, UNM Cancer Centre

13.10
Networking Lunch

14.00 CRISPR-Cas9 Screening to Identify Cancer Dependencies

  • Use of high-throughput genome-scale CRISPR-Cas9 screening to identify cancer dependencies
  • Identification and reconciliation of copy number effects in CRISPR-Cas9 negative selection screens
  • Future directions for CRISPR-Cas9 technology in cancer biology

Andrew Aguirre, Medical Oncologist, Dana-Farber Cancer Institute

14.30 Harnessing RNA targeting CRISPR systems for transcriptome engineering and human health

  • Background on key CRISPR-Cas13 RNA targeting features
  • Development of CRISPR-Cas13 for mammalian RNA knockdown and RNA viral therapeutics
  • Application of CRISPR-Cas13 for RNA enrichment and imaging
  • Application of CRISPR-Cas13 for therapeutic RNA editing

Omar O. Abudayyeh, Scientist, MIT

14.00 Using CRISPR to Generate Potent Allogeneic CAR T Therapeutics

  • CRISPR/cas9 enables multiplex editing in T Cells
  • Recombinant allogeneic CAR T cells are readily manufactured
  • System is readily applicable to many cancer targets

Jon Terret, Head of Immuno Oncology, CRISPR Therapeutics

14.30 CRISPR Genetic Circuits for Controllable Gene Therapies

  • Safety and controllability are two important features of future CRISPR therapies
  • Synthetic biology can enable control over the CRISPR technology for more sophisticated gene therapies
  • Synthetic CRISPR circuits and similar strategies can lead us towards this direction

Samira Kiani, Assistant Professor, Arizona State Univeristy

15.45
Afternoon refreshments

16.15
Gene Editing By CRISPR-Cas & Cpf1 In The Mouse Brain

Synopsis

  • AAV-based delivery strategies for gene editing in the brain
  • Single and multiplex editing using CRISPR-Cas and Cpf1 in neurons
  • Nuclei sorting of brain cells for analyzing genomic DNA and RNA

16.45
Safety Package and the Methods for Progression to CRISPR Clinical Trials

Synopsis

  • Effective on-target editing
  • Lack of detectible off-target events using genome-wide and bioinformatics-derived assays
  • Additional testing for safety package

17.15
Chair’s Closing Remarks

17.25
Close of the 4th Annual Precision CRSIPR Congress 2018